<DOC>
	<DOCNO>NCT01898286</DOCNO>
	<brief_summary>This extension study evaluate safety tolerability long-term treatment DiaPep277® determine long-term treatment effect DiaPep277® parameters metabolic control preservation beta-cell function subject long exposure DiaPep277® .</brief_summary>
	<brief_title>Open-Label Extension Study Evaluate Long Term Safety Treatment Effect DiaPep277®</brief_title>
	<detailed_description>Treatment DiaPep277® expect long-term ; stop treatment may result eventual loss preserve beta-cell function . Indeed , extension phase 2 study show patient initially treat DiaPep277® maintain initial beta-cell function , require continuation treatment , lose beta-cell function switch Placebo . These extension study small outcome statistically significant , suggested continuation treatment need long-term maintenance efficacy . Therefore , extension study , patient complete 1001 phase 3 study ( NCT01103284 ) maintain clinically significant beta-cell function offer 2-year continuation active treatment , since likely benefit use medication . The participation extension study offer eligible subject complete 1001 study , regardless treatment arm allocation initial study . By achieve long-term preservation beta-cell function , patient expect maintain good management disease , manifest good glycemic control few hypoglycemic event .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>patient type 1 diabetes participate 1001 study residual betacell function demonstrate stimulated Cpeptide ≥ 0.20 nmol/L . The subject significant ongoing disease condition likely affect subject 's response treatment The subject history kind malignant tumor . The subject clinical evidence diabetesrelated complication Subject history endogenous allergic reactivity : The subject know immune deficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>47 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>C peptide</keyword>
	<keyword>beta cell function</keyword>
	<keyword>immune modulation type 1 diabetes</keyword>
	<keyword>immune intervention type 1 diabetes</keyword>
</DOC>